GlassScriptPhysician profile
Rajeev Mehta
NPI 1114995545
$87,662.15
in general payments reported to CMS, 2019-2025
27 companies · $5,771 in 2025
The $5,771 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $5,009 · 2021: $24K · 2022: $20K · 2023: $28K · 2024: $3,664 · 2025: $5,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $3,743 · Travel and Lodging: $356 · Education: $96.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,349.00 |
| Food and Beverage | $3,743.40 |
| Travel and Lodging | $355.53 |
| Education | $96.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $79,113.67 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $4,972.89 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,330.38 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $542.57 | 2020-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $252.06 | 2023-2025 | Glassia |
| Mylan Specialty L.P. | $245.58 | 2022-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $137.00 | 2023-2024 | Xarelto |
| Amgen INC. | $110.02 | 2023-2025 | Tezspire, Uplizna |
| Grifols USA, LLC | $109.80 | 2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.08 | 2019-2023 | Stiolto Respimat |
| Philips North America LLC | $89.96 | 2022 | |
| Viatris Specialty LLC | $86.25 | 2025 | Yupelri |
| Pfizer INC. | $79.73 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2024 | |
| United Therapeutics Corporation | $74.42 | 2023-2025 | Tyvaso, Tyvaso |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $72.04 | 2025 | Ohtuvayre |
| Alexion Pharmaceuticals, INC. | $62.70 | 2025 | Ultomiris |
| Intuitive Surgical, INC. | $55.85 | 2024 | |
| Insmed, INC. | $36.96 | 2025 | Brinsupri |
| Integra Lifesciences Corporation | $28.43 | 2022-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Inspire Medical Systems, INC. | $23.06 | 2023 | Inspire |
| Resmed Corp | $20.69 | 2020 | |
| Mallinckrodt Hospital Products INC. | $17.25 | 2024 | Acthar |
| Kite Pharma, INC. | $13.45 | 2019 | |
| Pulmonx Corporation | $13.32 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.